类风湿关节炎接受糖皮质激素患者停用地舒单抗后的效应
该随机双盲安慰剂对照II期研究事后分析纳入82例基线接受糖皮质激素的类风湿关节炎患者,评估停用地舒单抗12个月后骨转换标志物与骨密度变化。停药后骨转换指标逐渐回升,腰椎和全髋骨密度在停药12个月后回到基线水平,期间未报告骨质疏松性骨折。
要点
- 停用地舒单抗后骨转换标志物逐渐升高,PINP在180mg组停药12个月时较安慰剂显著升高。
- 停药12个月后腰椎和全髋骨密度回到基线水平。
- 治疗及停药期间未报告骨质疏松性骨折。
核心结论
- 在短期使用地舒单抗的糖皮质激素治疗类风湿关节炎患者中,停药导致骨转换逐渐增加,并与腰椎和全髋骨密度回到基线相关。
研究设计与样本
- 随机双盲安慰剂对照II期研究的事后分析,纳入基线接受糖皮质激素的类风湿关节炎患者82例。
主要发现
- 两个地舒单抗组CTX和PINP自基线显著下降,停药后CTX回到基线且停药6和12个月时与安慰剂组无显著差异。
- 地舒单抗60mg组停药6和12个月时PINP自基线中位百分比变化分别为-0.16%和15.3%(vs安慰剂P=0.062和P=0.017)。
- 地舒单抗180mg组停药6和12个月时PINP自基线中位百分比变化分别为9.0%和75.8%(vs安慰剂P=0.018和P=0.002)。
- 与安慰剂相比,地舒单抗组腰椎和全髋骨密度增加,停药12个月后回到基线。
- 治疗期间及停药期间未报告骨质疏松性骨折。
临床怎么用
- 对接受糖皮质激素的类风湿关节炎患者短期使用地舒单抗后停药,需关注骨转换回升及骨密度回落至基线。
局限性
- 本文为事后分析,样本量有限(n=82),仅评估停药后12个月内的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase II study of RA patients. Patients received placebo, denosumab 60 mg, or denosumab 180 mg every 6 months for 12 months and were followed up for an additional 12 months after discontinuation, during which no bone loss prevention therapy was instituted. Changes from baseline in serum C-terminal telopeptide of type I collagen (CTX), serum procollagen type I N-terminal propeptide (PINP), and lumbar spine and total hip BMD were evaluated. RESULTS: In this post hoc analysis of patients treated with glucocorticoids at study baseline (n = 82), levels of CTX and PINP decreased significantly from baseline in both denosumab groups. Following denosumab discontinuation, CTX returned to baseline and was not significantly different from the placebo group 6 and 12 months after discontinuation. Median percentage changes from baseline PINP in those treated with denosumab 60 mg were -0.16% and 15.3% at 6 and 12 months, respectively, after discontinuation (P = 0.062 and P = 0.017, versus placebo); corresponding changes with denosumab 180 mg were 9.0% and 75.8%, respectively (P = 0.018 and P = 0.002 versus placebo). Compared to placebo, lumbar spine and total hip BMD increased in patients receiving denosumab and returned to baseline 12 months after discontinuation. No osteoporotic fractures were reported during treatment or in the off-treatment period. CONCLUSION: In this analysis of short-term denosumab use in RA patients receiving glucocorticoids, denosumab discontinuation resulted in a gradual increase in bone turnover, which was associated with a return to baseline lumbar spine and total hip BMD.
引用
- Saag KG, McDermott MT, Adachi J, et al. The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids. Arthritis Rheumatol. 2022. PMID: 34535967. doi:10.1002/art.41981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。